BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) is a commercial-stage biopharmaceutical company that discovers, develops and commercializes medicines for genetic diseases, focusing on conditions with significant unmet medical needs. Its portfolio includes approved and investigational therapies, and it serves patients through… From the company’s description.
Over the twelve months to Sep 30, 2026, BridgeBio Pharma, Inc. reported revenue of $945.54M, up 167.3% from a year earlier, and a net loss of $577.58M. Its operating margin was −38.5%, and operations used $368.97M in cash. In fiscal 2025, it reported revenue of $502.08M, up 126.3% from fiscal 2024, and a net loss of $732.94M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What BridgeBio Pharma, Inc. does
In the company’s own words
BridgeBio Pharma, Inc. (Nasdaq: BBIO) is a commercial-stage biopharmaceutical company that discovers, develops and commercializes medicines for genetic diseases, focusing on conditions with significant unmet medical needs. Its portfolio includes approved and investigational therapies, and it serves patients through its U.S. commercial organization and international partners. BridgeBio operates a decentralized hub-and-spoke model: dedicated teams advance individual programs, supported by centralized clinical, regulatory, business, finance and commercial functions. Its principal commercial product is Attruby (acoramidis), an oral treatment for transthyretin amyloid cardiomyopathy, marketed in the United States; outside the U.S., acoramidis is sold as Beyonttra through partners including Bayer in Europe and Alexion in Japan, as well as directly in certain markets. Its late-stage pipeline includes infigratinib for achondroplasia, BBP-418 for limb-girdle muscular dystrophy type 2I/R9, and encaleret for autosomal dominant hypocalcemia type 1. Other products include Nulibry, whose global rights were acquired by Sentynl, and Truseltiq, which is no longer commercially available. Attruby generated $362.4 million in U.S. net product revenue in 2025. Its website is https://bridgebio.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- PALO ALTO, CA
- Fiscal year end
- December
- CIK
- 1743881
- SIC
- 2834
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns BridgeBio Pharma, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in BridgeBio Pharma, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · BridgeBio Pharma, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
BridgeBio Pharma, Inc.’s bonds, as funds hold them
Funds report holding 4 issues of BridgeBio Pharma, Inc.’s debt, $502.47M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 1.72%, maturing 2027 to 2033.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do BridgeBio Pharma, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of BridgeBio Pharma, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in BridgeBio Pharma, Inc.'s last four quarterly filings that the numbers alone won't show?”